Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?
Metabolic syndrome is the latest moniker for an alliance of pathologic conditions that conspire to amplify the risk of atherosclerosis or type 2 diabetes. Several recent advances in the understanding of this condition have led to its widespread adoption in clinical practice, prompted by influential practice guidelines. In particular, guidelines relating to the management of hyperlipidemia and hypertension afford a prominent role for metabolic syndrome, as a risk factor and a target of therapy. In many ways, the scientific evidence base has not kept pace with the demand for treatment options, rendering therapy nebulous. Most prominently, we do not know whether to adopt a strategy based on a multi-pronged attack, or whether to concentrate our greatest efforts on attacking a critical weakness. We review the limited data available regarding metabolic syndrome, with a focus on expert opinion gleaned from clinical guidelines, and offer advice to the clinician from our own experience with this population.
Dunbar
R L
RL
University of Pennsylvania Medical School, Philadelphia, PA, USA. richard.dunbar@uphs.upenn.edu
Rader
D J
DJ
D001161:Arteriosclerosis / Q000503:physiopathology / Q000628:therapy; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology / Q000628:therapy; D006949:Hyperlipidemias / Q000503:physiopathology / Q000628:therapy; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D024821:Metabolic Syndrome / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy*; D009765:Obesity / Q000503:physiopathology / Q000628:therapy; D015995:Prevalence; D011379:Prognosis; D018570:Risk Assessment; D014481:United States / Q000453:epidemiology